Coeptis Therapeutics Holdings, Inc. (COEP)
NASDAQ: COEP · Real-Time Price · USD
0.190
-0.004 (-2.26%)
At close: Nov 21, 2024, 4:00 PM
0.192
+0.002 (1.05%)
After-hours: Nov 21, 2024, 5:23 PM EST
COEP Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
7.54M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
XWELL | 33.83M |
Ontrak | 11.24M |
Evoke Pharma | 8.62M |
NeuroMetrix | 3.77M |
Syros Pharmaceuticals | 386.00K |
Cardio Diagnostics Holdings | 35.69K |
COEP News
- 14 days ago - Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development - PRNewsWire
- 4 weeks ago - Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use - PRNewsWire
- 5 weeks ago - Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy - PRNewsWire
- 2 months ago - Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing - PRNewsWire
- 2 months ago - Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders - PRNewsWire
- 5 months ago - Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering - PRNewsWire
- 6 months ago - Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting - PRNewsWire
- 7 months ago - Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 - PRNewsWire